

Press Release

Apogenix to Present at Two Upcoming International Conferences

Heidelberg, Germany, May 4, 2016 – Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at BioEquity Europe 2016 and at the Jefferies 2016 Healthcare Conference.

BioEquity Europe 2016

Venue: Scandic Hotel, Copenhagen, Denmark

Presentation: May 10, 2016, 4:40 p.m. CEST, Ball Room 2

Jefferies 2016 Healthcare Conference

Venue: New York City, NY, USA

Presentation: June 7, 2016, 8:00 a.m. EDT

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.

Contact

Thomas Hoeger, Ph.D., CEO

Apogenix AG

Phone: +49 (6221) 58 60 80

E-Mail: contact@apogenix.com

Web: www.apogenix.com

Media Contacts

USA:

Matt Middleman, M.D.

Russo Partners, LLC

Phone: +1 (212) 845 4272

matt.middleman@russopartnersllc.com

Europe:

Raimund Gabriel

MC Services AG

Phone: +49 (89) 210 228 30

raimund.gabriel@mc-services.eu